Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 38 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S, COMPASS Investigators. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 2019;157:agosto. [Ref.ID 103177]
2. Cita con resumen
Ekelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Díaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim J-H, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Bruns NC, Misselwitz F, Chen E, Leong D, Yusuf S, for the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017:5 de octubre. [Ref.ID 102087]
3. Cita con resumen
O'Donoghue ML, Glaser R, Cavender MA, Alyward PE, Bonaca MP, Budaj A, Davies RY, Dellborg M, Fox KAA, Gutierrez JAT, Hamm C, Kiss RG, Kovar F, Kuder JF, Im KA, Lepore JJ, Lopez-Sendon JL, Ophuis TO, Parkhomenko A, Shannon JB, Spinar J, Tanguay J-F, Ruda M, Steg G, Theoux P, Wiviott SD, Laws I, Sabatine MS, Morrow DA, for the LATITUDE-TIMI 60 Investigators. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction. A randomized clinical trial. JAMA 2016;315:1591-9. [Ref.ID 100240]
4.Tiene citas relacionadas Cita con resumen
Washam JB, Stevens SR, Lokhnygina Y, Halperin JL, Breidthardt G, Singer DE, Mahaffey KW, Hankey GJ, Berkowtitz SD, Nessel CC, Fox KAA, Califf RM, Piccini JP, Patel MR, ROCKET AF Steering Committee and Investigators. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Lancet 2015;385:2363-70. [Ref.ID 99291]
5. Cita con resumen
Mahaffey KW, Wojdyla D, Hankey GJ, White HD, Nessel CC, Piccini JP, Patel MR, Berkowitz SD, Becker RC, Halperin JL, Singer DE, Califf RM, Fox KAA, Breithardt G, Hacke W. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med 2013;158:861-8. [Ref.ID 95680]
6.Tiene citas relacionadas
Fox KAA. Dual or single antiplatelet therapy with anticoagulation?. Lancet 2013;381:1080-1. [Ref.ID 95172]
7.Tiene citas relacionadas Cita con resumen
Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, Huber K, Chan MY, Cornel JH, Brown E, Zhou C, Jakubowski JA, White HD, Fox KAA, Prabhakaran D, Armstrong PW, Tantry US, Roe MT, for the TRILOGY ACS Platelet Function Substudy Investigators. Platelet function extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: The TRILOGY ACS Platelet Function Substudy. JAMA 2012;308:1785-94. [Ref.ID 94020]
8. Cita con resumen
Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KAA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJO, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA, for the TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366:1404-13. [Ref.ID 92750]
9. Cita con resumen
Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KAA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FWA, Gibson CM, for the ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19. [Ref.ID 92103]
10.Tiene citas relacionadas Cita con resumen
Patel MR, Fox KAA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. Author/editor response. N Engl J Med 2011;365:2335. [Ref.ID 91975]
11.Tiene citas relacionadas Cita con resumen
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithard G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JP, Berkowitz SD, Fox KAA, Califf RM, for the ROCKET AF investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91. [Ref.ID 90982]
12.Tiene citas relacionadas
Topol EJ, Bousser M-G, Fox KAA, Montelescot G. Termination of the CRESCENDO trial. Authors' reply. Lancet 2010;376:1984-5. [Ref.ID 89859]
13. Cita con resumen
Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KAA, Eikelboom JW. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010;363:1704-14. [Ref.ID 89554]
14.Tiene citas relacionadas Cita con resumen
Mehta S, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht H-J, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand J-P, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KAA, Yusuf S, on behalf of the CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in invididuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376:1233-43. [Ref.ID 89553]
15.Tiene citas relacionadas Cita con resumen
Topol EJ, Bousser M-G, Fox KAA, Creager MA, Despres J-P, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL, for The CRESCENDO Investigators. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010;376:517-23. [Ref.ID 89128]
16.Tiene citas relacionadas
Fowkes FGR, Price JF, Stewart MCW, Butcher I, Leng GC, Pell ACH, Sandercock PAG, Fox KAA, Lowe GDO, Murray GD, for the Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index. A randomized controlled trial. JAMA 2010;303:841-8. [Ref.ID 87977]
17.
O'Donoghue M, Boden WE, Braunwald E, Cannon CP, Clayton TC, de Winter RJ, Fox KAA, Lagerqvist B, McCullough PA, Murphy SA, Spacek R, Wallentin L, Windhausen F, Sabatine MS. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction. A meta-analysis. JAMA 2008;300:71-80. [Ref.ID 83435]
18. Cita con resumen
Fox KAA, Bassand J-P, Wallentin L, Theroux P, Piegas LS, Valentin V, Moccetti T, Chrolavicius S, Yusuf S, on behalf of the OASIS 5 Investigators. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2007;147:304-10. [Ref.ID 81026]
19.
Fox KAA, Steg PG, Eagle KA, Goodman SG, Anderson Jr FA, Granger CB, Flather MD, Budaj A, Quill A, Gore JM, for the GRACE Investigators. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297:1892-900. [Ref.ID 80008]
20.Tiene citas relacionadas Cita con resumen
Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, et al., for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17. [Ref.ID 76744]
Seleccionar todas
 
 1 a 20 de 38 siguiente >>